[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344282-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344282-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-impact-of-tumor-associated-stroma-in-triple-negative-breast-cancer-abstract-and-results","Prognostic impact of tumor-associated stroma in triple-negative breast cancer - Abstract and results","","Aim to establish histological categorization of tumor-associated stroma (TAS) reflecting the biological behavior of triple-negative breast cancer (TNBC). One-hundred-and-twenty surgically resected TNBC cases were examined, with TAS in the invasive frontal region classified into mature stroma (MS) and immature stroma (IS) based on myxoid stroma criteria. IS showed markedly lower high tumor-infiltrating lymphocytes (TILs) incidence, and significantly worse progression-free and overall survival. Cox multivariate regression identified IS as an independent indicator of poorer prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-impact-of-tumor-associated-stroma-in-triple-negative-breast-cancer-abstract-and-results/344282/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-impact-of-tumor-associated-stroma-in-triple-negative-breast-cancer-abstract-and-results/344282.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were tumor-associated stroma (TAS) subtypes defined in this study?","Question",{"text":63,"@type":64},"TAS in the invasive frontal region was categorized into mature stroma (MS) and immature stroma (IS). IS was assigned when the largest myxoid stroma filled a high-power magnification field; otherwise TAS was categorized as MS.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What proportion of TNBC cases showed immature versus mature stroma?",{"text":68,"@type":64},"Among 120 TNBC patients, 103 (85.8%) had mature stroma (MS) and 17 (14.2%) had immature stroma (IS).",{"name":70,"@type":61,"acceptedAnswer":71},"What prognostic significance did IS have compared with MS?",{"text":72,"@type":64},"Progression-free survival and overall survival curves differed between IS and MS. Multivariate Cox regression showed IS was an independent indicator of lower progression-free survival and overall survival rates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344282,1790279959,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Breast Cancer (2025) 32:347–356  \n[https://doi.org/10.1007/s12282-024-01661-8](https://doi.org/10.1007/s12282-024-01661-8)  \nPrognostic impact of tumor‑associated stroma in triple‑negative breast cancer  \nAkinari Kakumoto1 · Tsengelmaa Jamiyan2 · Ai Koyanagi1 · Hajime Kuroda1 · Rin Yamaguchi3 · Hitoshi Tsuda4 · Akira Hirano5 · Shunichi Shiozawa6  \nReceived: 26 September 2024 / Accepted: 13 December 2024 / Published online: 18 December 2024 © The Author(s) 2024  \nAbstract  \nAim To establish the histological categorization of tumor‑associated stroma (TAS) that reflects the biological behavior of triple‑negative breast cancer (TNBC) .  \nMethods and results One‑hundred‑and‑twenty surgically resected cases ofTNBC were examined. We histologically catego‑ rized the TAS in the invasive frontal region into two groups: mature stroma (MS) and immature stroma (IS) . The designation of IS was applied for tumors in which the largest myxoid stroma filled a high‑power magnification field. When there were no myxoid stroma that meet the criteria for IS, TAS was categorized as MS. The tumors with type MS were observed in 103 (85.8%) of patients, whereas 17 (14.2%) of patients had tumors with IS. In total, 72 out of 120 patients with TNBC exhibited high tumor‑infiltrating lymphocytes (TILs) representing 60% of the cohort. The incidences of high TILs were 66%(68 out of 103) in the MS group but only 23.5%(4 of 17) in the IS group (p = 0.001) . Progression‑free survival (PFS) and overall survival (OS) curves were different between IS and MS groups (p \u003C 0.001 each), and Cox multivariate regression analysis revealed that IS was an independent indicator for lower PFS and OS rates (p \u003C 0.001; p = 0.008) .  \nConclusion Our findings suggest that TAS characteristics, particularly the distinction between IS and MS, play a significant role in the prognosis ofTNBC. The presence of IS, associated with poor prognosis and low TILs, contrasts with the favorable outcomes observed in cases with MS. Understanding these TAS dynamics could aid in identifying patients with varying prognostic outcomes in TNBC, necessitating further research into the mechanisms behind these observations.  \nKeywords Tumor‑associated stroma · Triple‑negative breast cancer · Tumor‑infiltrating lymphocytes  \nIntroduction  \nAkinari Kakumoto and Tsengelmaa Jamiyan these authors have contributed equally to this work.  \n* Hajime Kuroda [kuroda.hajime@twmu.ac.jp](kuroda.hajime@twmu.ac.jp)  \n1 Department of Diagnostic Pathology, Tokyo Women’s Medical University Adachi Medical Center, 4‑33‑1 Kohoku, Adachi‑ku, Tokyo 123‑8558, Japan  \n2 Department of Pathology and Forensic Medicine, Mongolian National University of Medical Sciences, Ulan Bator 14210, Mongolia  \n3 Department of Diagnostic Pathology, Nagasaki University Hospital, 1‑7‑1 Sakamoto, Nagasaki City, Nagasaki 852‑8521, Japan  \nGene expression profiling studies have divided invasive breast cancer into several major subtypes [1] . Of these, the so‑called ‘triple‑negative breast carcinoma’ (TNBC) marked by the absence of estrogen receptor (ER) and progesterone  \n4 Department of Pathology II, National Defense Medical College, 3‑2 Namiki, Tokorozawa, Saitama 359‑8513, Japan  \n5 Department of Breast Surgery, Tokyo Women’s Medical University Adachi Medical Center, 4‑33‑1 Kohoku, Adachi‑ku, Tokyo 123‑8558, Japan  \n6 Department of Surgery, Tokyo Women’s Medical University Adachi Medical Center, 4‑33‑1 Kohoku, Adachi‑ku, Tokyo 123‑8558, Japan  \nreceptor (PgR) expression, as well as the lack of human epidermal growth factor receptor 2 (HER2) protein over‑ expression. This subtype is associated with an unfavorable prognosis [2, 3] .  \nAccording to current clinical guidelines for breast cancer, the treatment decisions are typically guided by pathologic factors routinely assessed in clinical practice. Important factors influencing breast cancer prognosis and treatment decisions include primary tumor size, lymph node status, tumor grade, hormonal receptor ","cbCaithfmJOL2edj","https://ap.wps.com/l/cbCaithfmJOL2edj","pdf",1569865,"English","# Abstract\n## Aim\n## Methods and results\n## Conclusion\n# Introduction","[{\"question\":\"How were tumor-associated stroma (TAS) subtypes defined in this study?\",\"answer\":\"TAS in the invasive frontal region was categorized into mature stroma (MS) and immature stroma (IS). IS was assigned when the largest myxoid stroma filled a high-power magnification field; otherwise TAS was categorized as MS.\"},{\"question\":\"What proportion of TNBC cases showed immature versus mature stroma?\",\"answer\":\"Among 120 TNBC patients, 103 (85.8%) had mature stroma (MS) and 17 (14.2%) had immature stroma (IS).\"},{\"question\":\"What prognostic significance did IS have compared with MS?\",\"answer\":\"Progression-free survival and overall survival curves differed between IS and MS. Multivariate Cox regression showed IS was an independent indicator of lower progression-free survival and overall survival rates.\"}]","Prognostic impact of tumor-associated stroma in triple-negative breast cancer - Abstract and results | PDF",1790053340,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6311adcabcb889b726d2eaa5b59e8794.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b87c5b4b00186c34d7172e753625aab2.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9eef356a5e790cc33ed1c971f04ae6ea.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b936a1ecc1b20daa78e82fd302bcfbf9.webp",980,1301]